

Ref: COR/2026/09-1(L)
Date: September 17, 2026

The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi.

MATERIAL INFORMATION

Dear Sir,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, we hereby convey the following information:

Ferozsons Laboratories Limited (PSX: FEROZ) has entered into a royalty-free voluntary licensing agreement for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement, expanded from the existing twice-yearly lenacapavir for HIV prevention access strategy, covers 120 high-incidence countries (which are primarily low- and lower- middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial is ongoing. Ferozsons is one of the six global partners to have successfully signed the expanded voluntary license agreement with Gilead to produce high-quality generic of lenacapavir.

Once yearly lenacapavir, if approved, could provide a full year of HIV prevention with a single dose, expanding prevention choice and helping address barriers that can limit PrEP uptake and persistence. The expanded agreements represent one of the earliest HIV prevention access planning efforts undertaken during Phase 3 development and build on Gilead's two decades of experience developing global access pathways for HIV medicines, including unprecedented work for twice yearly lenacapavir.

About Lenacapavir

Twice-yearly lenacapavir is approved in multiple countries as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents who are at risk of HIV acquisition. Lenacapavir is also approved in multiple countries for the treatment of multi-drug-resistant HIV in adults, in combination with other antiretrovirals.

The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes. Lenacapavir is being evaluated as a long-acting option in multiple



☐ **Head Office/Biotech Factory:**

5 - KM, Sundar Raiwind Road
Raiwind (55150), Pakistan
Tel: (+92 42) 3602 6700
Fax: (+92 42) 3602 6701-02

☐ **Registered Office:**

197 - A, The Mall, Rawalpindi
(46000), Pakistan
Tel: (+92 51) 4252 155-57
Fax: (+92 51) 4252 153

☐ **Pharma Factory:**

P. O. Ferozsons, Nowshera
(24160), KPK, Pakistan
Tel: (+92 923) 560141
(+92 923) 560145
(+92 923) 560148
(+92 923) 560056

☐ **Lahore Sales Office:**

43 - Al Noor Building, Bank
Square, The Mall, Lahore
(54000), Pakistan
Tel: (+92 42) 3735 8194
Fax: (+92 42) 3731 3680

☐ **Karachi Sales Office:**

House No. 9, Maqbool Cooperative
Housing Society, Shahr-e-Faisal
Karachi (75350), Pakistan
Tel: (+92 21) 3438 6852
Fax: (+92 21) 3438 6754

ongoing and planned early and late-stage clinical studies in Gilead's HIV prevention and treatment research program, including a once-yearly injection for HIV prevention.

Under this non-exclusive license, Ferozsons can manufacture and sell, subject to required regulatory approvals, its licensed generic of Gilead proprietary compound Lenacapavir in 120 (one hundred twenty) primarily low- and lower- middle income countries. Under the licensing agreement, the company has a right to receive a technology transfer of the Gilead manufacturing process for lenacapavir to enable it to scale up production.

Ferozsons Laboratories is actively preparing for upcoming generic availability, reflecting continued momentum toward making twice-yearly HIV prevention medicine available to more people in the regions with the greatest unmet need. The injectable drug product will be manufactured at Ferozsons' JV Subsidiary, BF Biosciences Limited (BFBIO) under a contract manufacturing agreement and will be sold by Ferozsons, while the oral variant will be manufactured and sold by Ferozsons directly.

You are requested to please disseminate the above information to TREC Holders of the Exchange accordingly.

Thank you.

Yours truly,




Syed Ghausuddin Saif
Company Secretary

CC: Director Enforcement – Securities and Exchange Commission of Pakistan.



☐ **Head Office/Biotech Factory:**

5 - KM, Sundar Raiwind Road
Raiwind (55150), Pakistan
Tel: (+92 42) 3602 6700
Fax: (+92 42) 3602 6701-02

☐ **Registered Office:**

197 - A, The Mall, Rawalpindi
(46000), Pakistan
Tel: (+92 51) 4252 155-57
Fax: (+92 51) 4252 153

☐ **Pharma Factory:**

P. O. Ferozsons, Nowshera
(24160), KPK, Pakistan
Tel: (+92 923) 560141
(+92 923) 560145
(+92 923) 560148
(+92 923) 560056

☐ **Lahore Sales Office:**

43 - Al Noor Building, Bank
Square, The Mall, Lahore
(54000), Pakistan
Tel: (+92 42) 3735 8194
Fax: (+92 42) 3731 3680

☐ **Karachi Sales Office:**

House No. 9, Maqbool Cooperative
Housing Society, Shahrah-e-Faisal
Karachi (75350), Pakistan
Tel: (+92 21) 3438 6852
Fax: (+92 21) 3438 6754